Alzheimer’s research has come a long way in recent years. Blood tests to identify an abnormal protein called ptau217 can mean diagnosing Alzheimer’s disease before symptoms like memory loss show up.

Early intervention is key, says Dr. Rany Aburashed, a neurologist and CEO of Neurogen Biomarking.

“The whole game now is determining as early as possible if you have these plaques developing in the brain. The earlier we know, before the symptoms are significant, the more we can interact and actually change the disease itself.”

The blood tests identify sticky amyloid plaques and tangled fibers, which are the hallmarks of Alzheimer’s disease.

Diagnosing Alzheimer’s based on biology instead of symptoms means early interventions could reduce progression or severity of Alzheimer’s symptoms later in life.

“Just because you have a genetic predisposition, it does not mean you’re going to progress to dementia […] but you can only change that if you’re in front of it,” says Dr. Aburashed.

Some people have genetic predispositions, and lifestyle factors in 40’s, 50’s and 60’s can trigger the disease, especially drinking alcohol and smoking, adds Dr. Aburashed.

The FDA approved several new tests for Alzheimer’s diagnosis this year.

Subscribe to The Metro on Apple Podcasts, Spotify, NPR.org or wherever you get your podcasts.

Listen to The Metro weekdays from 10 a.m. to noon ET on 101.9 FM and streaming on demand.

More stories from The Metro